Please ensure Javascript is enabled for purposes of website accessibility
Accessibility Menu

Podcasts > Archived Podcasts > Industry Focus

This show is no longer producing new episodes. Check out our other shows.

Industry Focus

Industry Focus Logo

Healthcare: Is It (Finally) OK To Buy Valeant and Gilead Sciences Again?

May 17, 2017 (23:44)

We dig into Valeant and Gilead Sciences' first quarter financials to see if shares are a bargain, or a bust.

Thanks to Slack for supporting The Motley Fool.  Learn more at http://www.slack.com">slack.com.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.